Rich-Vicks USA
Executive Summary
President William Bergman will retire from the Procter & Gamble subsidiary on June 30. President since 1987, he reports directly to P&G Group VP Malcolm Jozoff. In December 1988, Bergman was elected P&G's VP for Rich-Vicks. Bergman has been with Richardson-Vicks since 1950, holding a number of marketing and financial posts over the years. He also served as chairman of the Nonprescription Drug Manufacturers Association from 1987-1989. Acquired by P&G in 1985, Rich-Vicks employs 650 people.
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.